Multi-target therapeutics: when the whole is greater than the sum of the parts.
about
Discovery and resupply of pharmacologically active plant-derived natural products: A reviewHow drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusionTowards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examplesUpdate of TTD: Therapeutic Target DatabaseRational approaches to improving selectivity in drug designStructure and dynamics of molecular networks: a novel paradigm of drug discovery: a comprehensive reviewQuantitative phenotypic and pathway profiling guides rational drug combination strategiesMetabolomics and systems pharmacology: why and how to model the human metabolic network for drug discoveryNetwork connectivity during mergers and growth: Optimizing the addition of a moduleA ranking method for the concurrent learning of compounds with various activity profiles.Synergy Maps: exploring compound combinations using network-based visualizationThe antitumor effects of geraniol: Modulation of cancer hallmark pathways (Review)Engineered Nanoparticles Against MDR in Cancer: The State of the Art and its Prospective.Combination therapeutics in complex diseasesEfficient discovery of anti-inflammatory small-molecule combinations using evolutionary computingMechanistic and functional differentiation of tapentadol and tramadolDual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugsIron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseasesSearch algorithms as a framework for the optimization of drug combinations.Drug discovery using chemical systems biology: identification of the protein-ligand binding network to explain the side effects of CETP inhibitorsDrug discovery using chemical systems biology: repositioning the safe medicine Comtan to treat multi-drug and extensively drug resistant tuberculosisDrug inhibition profile prediction for NFκB pathway in multiple myelomaDrug discovery using chemical systems biology: weak inhibition of multiple kinases may contribute to the anti-cancer effect of nelfinavirExistence of inverted profile in chemically responsive molecular pathways in the zebrafish liverMitochondrial pathway mediates the antileukemic effects of Hemidesmus indicus, a promising botanical drugCore site-moiety maps reveal inhibitors and binding mechanisms of orthologous proteins by screening compound librariesA systems biology approach to drug targets in Pseudomonas aeruginosa biofilmSynergism and rules from combination of Baicalin, Jasminoidin and Desoxycholic acid in refined Qing Kai Ling for treat ischemic stroke mice modelWhat does it take to synergistically combine sub-potent natural products into drug-level potent combinations?An innovative strategy for dual inhibitor design and its application in dual inhibition of human thymidylate synthase and dihydrofolate reductase enzymesControllability in cancer metabolic networks according to drug targets as driver nodesThe anti-tumor histone deacetylase inhibitor SAHA and the natural flavonoid curcumin exhibit synergistic neuroprotection against amyloid-beta toxicityA network pharmacology study of Chinese medicine QiShenYiQi to reveal its underlying multi-compound, multi-target, multi-pathway mode of actionPooled screening for synergistic interactions subject to blocking and noiseThe use of functional chemical-protein associations to identify multi-pathway renoprotectantsASDCD: antifungal synergistic drug combination databaseVisualization of network target crosstalk optimizes drug synergism in myocardial ischemiaSynergistic interaction between selective drugs in cell populations modelsA Network-Based Target Overlap Score for Characterizing Drug Combinations: High Correlation with Cancer Clinical Trial ResultsNLLSS: Predicting Synergistic Drug Combinations Based on Semi-supervised Learning
P2860
Q22252341-D51E285B-94FE-411F-94C0-40974B4AA14EQ24273350-8EB32F9E-168F-4675-AA01-AA6ECB01CB1FQ24289511-016D2F4E-841E-4DD1-8A7C-10BA9584B225Q24643206-99D22E3D-5CDA-4A6E-82DA-31375390D01AQ26865357-E7B5E123-B442-4445-A2C8-95432D3009F6Q27008867-4F8D9A86-D844-4118-9134-F3A2E89266FAQ27021150-F1F00D56-0504-4FD8-AF9F-0E2B700B0C0CQ27144251-9550461A-791C-4144-8F5A-D2AA9F15A33AQ27444499-C8EE7476-633F-49DB-B573-BAAA487149EAQ27902271-E5499ED1-9A47-4483-98C7-43B5789FF5B1Q27902355-C835A615-828D-4D7D-98EF-E500556483ECQ28067149-6C8DDE2E-EA1A-426E-80F6-263234C43E54Q28073956-50FCFB43-C834-4945-97AC-72C30EE87430Q28076891-6BF542B7-AAB0-4F28-853E-867E85342FC5Q28251171-0BA8D485-A9FC-4370-AEB0-1C6A1FDDFC50Q28268772-C98F2A34-4C18-46BA-9F89-55B9506256D1Q28305100-EE3F19BF-3301-40C3-A065-34354987A2E7Q28388335-646FE94D-9CB3-4344-AA17-B5A1383ABA2DQ28474246-168C2365-02B7-4BDF-B5F1-521149B2BC50Q28475474-221807E1-E7DA-4D30-983B-C6E8D1D1440CQ28475676-0EB389DA-96F3-4EEC-B778-77FDE602BFEDQ28477374-5C9B1E17-C6E6-40C7-9B95-CCDCE02B358DQ28477930-563260B5-7FC0-467C-8728-C06D4B368D94Q28478180-BB66AE08-9CBF-4CE9-A7D2-3463D47E648BQ28478861-020B0E34-471B-4132-AABA-2A8C9D097B43Q28481318-E0D210E3-1DBE-4497-92C5-590FC1323A1FQ28482361-A1F5DCBB-55CB-47D0-BAEC-CD8334D4C96DQ28484057-83DABD32-FAD7-47C1-9B11-5A27259262FDQ28485360-3520F16C-09DE-4F3D-AF92-03C29C65BBC8Q28486030-B7CE9000-78C4-4F64-A7FE-4D8661BA2C8BQ28535399-84FE157C-FA01-4F0F-8840-4EFA4AB9051BQ28538399-711A5AAD-E31F-496D-AAD1-36E6C865B7A4Q28538646-6D8C959E-80F0-439F-8690-782F84E017A9Q28538785-F8644407-E513-448F-B85B-B96D5A597F2EQ28538871-41E81F41-F813-41DD-99DD-B8AAE31DEAD6Q28539135-CDC2B598-3481-4B06-9964-AE04D3B72FFDQ28539539-5B60F002-458B-4812-A66A-8731D0A70214Q28543382-EE03A235-7179-41C2-B5A4-BDB62CE193A8Q28547962-34CC12DC-7826-4B46-9EE0-D5CCAC2A850CQ28552626-B5A1D0B1-BD65-468F-8C8C-1A327981A334
P2860
Multi-target therapeutics: when the whole is greater than the sum of the parts.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Multi-target therapeutics: when the whole is greater than the sum of the parts.
@ast
Multi-target therapeutics: when the whole is greater than the sum of the parts.
@en
type
label
Multi-target therapeutics: when the whole is greater than the sum of the parts.
@ast
Multi-target therapeutics: when the whole is greater than the sum of the parts.
@en
prefLabel
Multi-target therapeutics: when the whole is greater than the sum of the parts.
@ast
Multi-target therapeutics: when the whole is greater than the sum of the parts.
@en
P2093
P1433
P1476
Multi-target therapeutics: when the whole is greater than the sum of the parts.
@en
P2093
Curtis T Keith
Grant R Zimmermann
Joseph Lehár
P356
10.1016/J.DRUDIS.2006.11.008
P577
2006-11-28T00:00:00Z